Citation & Authors
J R Soc Med. 2025;118(11):347-357.
ABSTRACT · RESEARCH SUMMARY
Research summary
This Taiwanese National Health Insurance study included patients with diabetes but no macrovascular or microvascular disease and performed separate matched comparisons with DPP-4 inhibitors, sulfonylureas, and GLP-1 drugs. SGLT2 inhibitor use was associated with fewer coronary heart disease events, heart failure, dialysis, sight-threatening retinopathy, amputations, and deaths. These findings cover multiple outcomes, and residual differences between treatment populations remain a concern.
Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗
